HNB
MLYS icon

Huntington National Bank’s Mineralys Therapeutics MLYS Stock Holding History

Huntington National Bank’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-166
Closed -$1.54K – 3915
2023
Q3 		$1.54K Buy
+166
New +$2.17K ﹤0.01% 2119

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Huntington National Bank's MLYS Position: Q4 2023 in Review

Huntington National Bank sold out of Mineralys Therapeutics (MLYS) in Q4 2023, closing a stake of 166 shares — an estimated $1.54K sold.

Huntington National Bank first reported a position in MLYS in Q3 2023 and held it in 1 quarter. The position peaked at $1.54K in Q3 2023. 87 funds tracked by Wall St. Rank hold MLYS as of Q4 2023.

  • Huntington National Bank reported no remaining Mineralys Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Huntington National Bank sold 166 Mineralys Therapeutics shares in Q4 2023, an estimated $1.54K.
  • Huntington National Bank first reported a position in Mineralys Therapeutics in Q3 2023 and held it in 1 quarter.
  • Huntington National Bank's Mineralys Therapeutics position peaked at $1.54K in Q3 2023.
  • 87 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2023.

Based on Huntington National Bank's 13F filing for Q4 2023, filed 7 Feb 2024.